Wet Age-Related Macular Degeneration
Pipeline by Development Stage
Drug Modality Breakdown
Ophthalmology is a $3.7B market with a mature, consolidating portfolio dominated by glaucoma treatments and emerging corneal/retinal therapies.
Key Trends
- Glaucoma therapeutics (prostaglandin analogs, adrenergic agents) represent 60%+ of spending but face patent cliffs 2028-2034
- Innovative mechanisms (NGF agonists, LFA-1 antagonists, RTKIs) gaining traction in dry eye and retinal disease segments
- Heavy trial activity (2,656 total) skewed toward Phase 4 (369) and Phase 3 (442), indicating mature clinical development landscape
Career Verdict
Ophthalmology offers stable mid-career opportunities with strong Commercial and Medical Affairs salaries, but limited innovation catalysts and significant patent cliff risk warrant careful timing of entry.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | LUMIGAN (Bimatoprost) | AbbVie | $697M | 19% | LOE_APPROACHING | Declining | |
| 2 | OXERVATE (Cenegermin-BKBJ) | Unspecified | $493M | 13% | PEAK | Stable | |
| 3 | XIIDRA (Lifitegrast) | Bausch + Lomb | $473M | 13% | PEAK | Stable | 7.6yr |
| 4 | INLYTA (Axitinib) | Pfizer | $467M | 13% | PEAK | Growing | 11.2yr |
| 5 | HUMIRA (Adalimumab) | AbbVie | $258M | 7% | LOE_APPROACHING | Declining |
Drug Class Breakdown
mature, losing exclusivity
peak growth in corneal disease
sustained peak sales
expanding in retinal indications
mature, multiple LOE approaching
mature, losing exclusivity
mature immunology approach
Career Outlook
StableOphthalmology offers predictable mid-career growth with strong Commercial ($158K) and Medical Affairs ($247K) compensation but faces structural headwinds: patent cliffs 2028-2034 eliminate $97M in revenue, glaucoma franchise maturity limits blockbuster potential, and modest trial volume (2,656) signals incremental R&D expansion. Best suited for professionals seeking stable roles in established therapeutic areas rather than disruptive innovation.
Breaking In
Enter via Clinical Operations or Commercial analyst roles at CROs (Syneos 210 jobs) or large diagnostics players (Labcorp 904) to build domain expertise before targeting pharma MSL/Medical Affairs positions.
For Experienced Professionals
Experienced professionals should prioritize Medical Affairs and Market Access roles leveraging mature market knowledge; avoid product-specific expertise in glaucoma due to patent cliff concentration, and consider adjacent areas (retinal, corneal) where innovation catalysts remain.
In-Demand Skills
Best For
Hiring Landscape
Ophthalmology hiring (3,202 jobs) is distributed across diagnostics/devices (Labcorp 904, Abbott 348) and pharma commercial functions rather than concentrated in R&D. Top pharmaceutical employers (Pfizer 60, AstraZeneca 100, Regeneron 168) show modest pharma-specific headcount relative to market size, suggesting outsourced CRO and distributor dependency. Medical Affairs ($247K avg salary) commands premium compensation, signaling high barrier to entry but strong mid-career upside.
Top Hiring Companies
By Department
Clinical Operations and Commercial roles offer entry-level stability ($150K-$158K); Medical Affairs commands premium salaries ($247K) but requires advanced credentials; limited R&D hiring (207 jobs) suggests constrained innovation investment.
Competitive Landscape
14 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 19 trials with date data
Clinical Trials (20)
Total enrollment: 2,959 patients across 20 trials
Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration
Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
Efficacy and Safety of RC28-E Versus Aflibercept
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
Clinical Study on the Efficacy and Safety of BAT5906 Injection
Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration
Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration
Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
ADVM-022 Intravitreal Gene Therapy for Wet AMD
The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)
Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD
Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration
Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
Related Jobs in Ophthalmology
Associate Director, U.S. Marketing Ophthalmology HCP Field Execution
Associate Director, U.S. Marketing Ophthalmology HCP Field Execution
Technical Writer
IT Support Specialist
Ophthalmology Account Manager - Midlands
Ophthalmology Account Manager - East of England
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.